organization · Reporting owner
Aisling Capital Partners IV, LP
Disclosed activity across 3 companies
Sign in to followReported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Elevation Oncology, Inc.ELEV · Entity 77243 | 10% owner | June 16, 2023 | June 21, 2023 |
| Viracta Therapeutics, Inc.SNSS · Entity 85616 | 10% owner | July 15, 2019 | July 15, 2019 |
| Zosano Pharma CorpZSAN · Entity 12518 | 10% owner | December 02, 2019 | December 06, 2019 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Elevation Oncology, Inc.
Report date June 16, 2023 · Filed June 21, 2023
Jointly reported with Aisling Capital IV, LP, Aisling Capital Partners IV LLC, ELMS STEVE, SCHIFF ANDREW N
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $1.47 · Expires 2033-06-15 | IndirectSee footnote | 31,238 |
Reported balance
After 2023-06-16 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2023-06-16 · Grant · Acquired 31,238 · Balance 31,238 F1: The stock option vests as to 100% of the total shares on the one-year anniversary of the grant date, subject to the Reporting Person's provision of service to the Issuer on such vesting date. F2: This stock option was granted to Steven Elms, an employee of Aisling Capital, in his capacity as a director of the Issuer. Pursuant to the policies of Aisling Capital, Mr. Elms does not have any right to any of the Issuer's securities issued as part of his service on the Board and Aisling Capital is entitled to receive all of the pecuniary interest in the securities issued. |
Filing footnotes · ownership attribution and instrument terms
F1: The stock option vests as to 100% of the total shares on the one-year anniversary of the grant date, subject to the Reporting Person's provision of service to the Issuer on such vesting date.
F2: This stock option was granted to Steven Elms, an employee of Aisling Capital, in his capacity as a director of the Issuer. Pursuant to the policies of Aisling Capital, Mr. Elms does not have any right to any of the Issuer's securities issued as part of his service on the Board and Aisling Capital is entitled to receive all of the pecuniary interest in the securities issued.
Viracta Therapeutics, Inc.
Report date July 15, 2019 · Filed July 15, 2019
Jointly reported with Aisling Capital IV, LP, Aisling Capital Partners IV LLC, SCHIFF ANDREW N, ELMS STEVE
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | IndirectSee footnote | 10,100,000 |
Reported balance
After 2019-07-15 transaction · row 1
Joint disclosure: continuity of the reported position is unresolved; see ownership footnotes.
1 source rowRow 1 · 2019-07-15 · Purchase · Acquired 2,500,000 · Balance 10,100,000 F1: Shares held by Aisling Capital IV, LP ("Aisling"). Aisling Capital Partners IV, LP ("Aisling GP"), is the general partner of Aisling. Aisling Capital Partners IV LLC ("Aisling Partners"), is the general partner of Aisling GP. The individual managing members ("the Aisling Managers"), of Aisling Partners are Andrew Schiff, M.D. and Steve Elms. By virtue of these relationships, Aisling GP, Aisling Partners and the Aisling Managers may be deemed to have voting and investment power over the shares held by Aisling. Each of the reporting persons, other than Aisling, disclaims beneficial ownership of the shares held by Aisling, except to the extent of any pecuniary interest therein, if any. |
Filing footnotes · ownership attribution and instrument terms
F1: Shares held by Aisling Capital IV, LP ("Aisling"). Aisling Capital Partners IV, LP ("Aisling GP"), is the general partner of Aisling. Aisling Capital Partners IV LLC ("Aisling Partners"), is the general partner of Aisling GP. The individual managing members ("the Aisling Managers"), of Aisling Partners are Andrew Schiff, M.D. and Steve Elms. By virtue of these relationships, Aisling GP, Aisling Partners and the Aisling Managers may be deemed to have voting and investment power over the shares held by Aisling. Each of the reporting persons, other than Aisling, disclaims beneficial ownership of the shares held by Aisling, except to the extent of any pecuniary interest therein, if any.
Zosano Pharma Corp
Report date December 02, 2019 · Filed December 06, 2019
Jointly reported with Aisling Capital IV, LP, Aisling Capital Partners IV LLC, ELMS STEVE, SCHIFF ANDREW N
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common Stock, par value of $0.0001SEC Table I · non-derivative | Direct | 2,718,226 |
Reported balance
After 2019-12-02 transaction · row 1
Joint disclosure: continuity of the reported position is unresolved; see ownership footnotes.
1 source rowRow 1 · 2019-12-02 · Grant · Acquired 689,655 · Balance 2,718,226 F1: The securities are directly held by Aisling Capital IV, LP ("Aisling"), and may be deemed to be beneficially owned by Aisling Capital Partners IV, LP ("Aisling GP"), as general partner of Aisling, Aisling Capital Partners IV LLC ("Aisling Partners"), as general partner of Aisling GP, and each of the individual managing members and partners (collectively, the "Managers") of Aisling GP and Aisling Partners. The Managers of Aisling Partners are Dr. Andrew Schiff and Steve Elms. |
Filing footnotes · ownership attribution and instrument terms
F1: The securities are directly held by Aisling Capital IV, LP ("Aisling"), and may be deemed to be beneficially owned by Aisling Capital Partners IV, LP ("Aisling GP"), as general partner of Aisling, Aisling Capital Partners IV LLC ("Aisling Partners"), as general partner of Aisling GP, and each of the individual managing members and partners (collectively, the "Managers") of Aisling GP and Aisling Partners. The Managers of Aisling Partners are Dr. Andrew Schiff and Steve Elms.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| June 16, 2023 Filed Jun 21, 2023 16:09 UTC | Elevation Oncology, Inc. ELEV · Entity 77243 | GrantStock Option (Right to Buy) · Derivative | 31,238 | $0.00 Strike: $1.47 | $0.00 |
DisclosureSEC source: 0001415889-23-010090 · form4-06212023_080601.xml · derivative · entry 1 Aisling Capital IV, LP · CIK 0001652910 · 10% owner Aisling Capital Partners IV LLC · CIK 0001737019 · 10% owner Aisling Capital Partners IV, LP · CIK 0001737020 · 10% owner ELMS STEVE · CIK 0001250195 · 10% owner SCHIFF ANDREW N · CIK 0001172252 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Indirect · See footnote Disclosed balance after: 31,238 Underlying: Common Stock · 31,238 shares Expires 2033-06-15 F1 · derivative.exercise_date: The stock option vests as to 100% of the total shares on the one-year anniversary of the grant date, subject to the Reporting Person's provision of service to the Issuer on such vesting date. F2 · ownership.nature: This stock option was granted to Steven Elms, an employee of Aisling Capital, in his capacity as a director of the Issuer. Pursuant to the policies of Aisling Capital, Mr. Elms does not have any right to any of the Issuer's securities issued as part of his service on the Board and Aisling Capital is entitled to receive all of the pecuniary interest in the securities issued. Read SEC document |
| June 17, 2022 Filed Jun 22, 2022 18:43 UTC | Elevation Oncology, Inc. ELEV · Entity 77243 | GrantStock Option (Right to Buy) · Derivative | 15,619 | $0.00 Strike: $1.31 | $0.00 |
DisclosureSEC source: 0001209191-22-038760 · doc4.xml · derivative · entry 1 Aisling Capital IV, LP · CIK 0001652910 · 10% owner Aisling Capital Partners IV LLC · CIK 0001737019 · 10% owner Aisling Capital Partners IV, LP · CIK 0001737020 · 10% owner ELMS STEVE · CIK 0001250195 · Director · 10% owner SCHIFF ANDREW N · CIK 0001172252 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 15,619 Underlying: Common Stock · 15,619 shares Expires 2032-06-16 F1 · derivative.exercise_date: The stock option vests as to 100% of the total shares on the one year anniversary of the grant date, subject to the Reporting Person's provision of service to the Issuer on such vesting date. F2 · ownership.nature: This stock option was granted to Steven Elms, an employee of Aisling Capital, in his capacity as a director of the Issuer. Pursuant to the policies of Aisling Capital, Mr. Elms does not have any right to any of the Issuer's securities issued as part of his service on the Board and Aisling Capital is entitled to receive all of the pecuniary interest in the securities issued. Read SEC document |
| June 29, 2021 Filed Jul 1, 2021 18:29 UTC | Elevation Oncology, Inc. ELEV · Entity 77243 | ConversionSeries B Preferred Stock · Derivative | 1,936,834 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-21-044561 · doc4.xml · derivative · entry 5 Aisling Capital IV, LP · CIK 0001652910 · 10% owner Aisling Capital Partners IV LLC · CIK 0001737019 · 10% owner Aisling Capital Partners IV, LP · CIK 0001737020 · 10% owner ELMS STEVE · CIK 0001250195 · Director · Managing Member SCHIFF ANDREW N · CIK 0001172252 · Managing Member Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 458,360 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: The Shares of the Issuer's Preferred Stock automatically converted on a 4.225582-for-one basis into the number of shares of the Issuer's Common Stock in shown in column 7 immediately upon the closing of the Issuer's initial public offering, and had no expiration date. F1 · derivative.exercise_date: The Shares of the Issuer's Preferred Stock automatically converted on a 4.225582-for-one basis into the number of shares of the Issuer's Common Stock in shown in column 7 immediately upon the closing of the Issuer's initial public offering, and had no expiration date. F1 · derivative.expiration_date: The Shares of the Issuer's Preferred Stock automatically converted on a 4.225582-for-one basis into the number of shares of the Issuer's Common Stock in shown in column 7 immediately upon the closing of the Issuer's initial public offering, and had no expiration date. F2 · ownership.direct: The securities are directly held by Aisling Capital IV, LP ("Aisling"). Aisling Capital Partners IV, LP ("Aisling GP"), is the general partner of Aisling, and Aisling Capital Partners IV LLC ("Aisling Partners"), is the general partner of Aisling GP. The managers of Aisling Partners are Dr. Andrew Schiff and Steve Elms and may share voting power and dispositive powers over securities held by Aisling, and as a result, may be deemed to have beneficial ownership over such securities. Each of the reporting persons disclaims beneficial ownership of the reported securities except to the extent of such reporting person's pecuniary interest therein. Read SEC document |
| June 29, 2021 Filed Jul 1, 2021 18:29 UTC | Elevation Oncology, Inc. ELEV · Entity 77243 | ConversionSeries A Preferred Stock · Derivative | 8,000,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-21-044561 · doc4.xml · derivative · entry 4 Aisling Capital IV, LP · CIK 0001652910 · 10% owner Aisling Capital Partners IV LLC · CIK 0001737019 · 10% owner Aisling Capital Partners IV, LP · CIK 0001737020 · 10% owner ELMS STEVE · CIK 0001250195 · Director · Managing Member SCHIFF ANDREW N · CIK 0001172252 · Managing Member Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 1,893,232 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: The Shares of the Issuer's Preferred Stock automatically converted on a 4.225582-for-one basis into the number of shares of the Issuer's Common Stock in shown in column 7 immediately upon the closing of the Issuer's initial public offering, and had no expiration date. F1 · derivative.exercise_date: The Shares of the Issuer's Preferred Stock automatically converted on a 4.225582-for-one basis into the number of shares of the Issuer's Common Stock in shown in column 7 immediately upon the closing of the Issuer's initial public offering, and had no expiration date. F1 · derivative.expiration_date: The Shares of the Issuer's Preferred Stock automatically converted on a 4.225582-for-one basis into the number of shares of the Issuer's Common Stock in shown in column 7 immediately upon the closing of the Issuer's initial public offering, and had no expiration date. F2 · ownership.direct: The securities are directly held by Aisling Capital IV, LP ("Aisling"). Aisling Capital Partners IV, LP ("Aisling GP"), is the general partner of Aisling, and Aisling Capital Partners IV LLC ("Aisling Partners"), is the general partner of Aisling GP. The managers of Aisling Partners are Dr. Andrew Schiff and Steve Elms and may share voting power and dispositive powers over securities held by Aisling, and as a result, may be deemed to have beneficial ownership over such securities. Each of the reporting persons disclaims beneficial ownership of the reported securities except to the extent of such reporting person's pecuniary interest therein. Read SEC document |
| June 29, 2021 Filed Jul 1, 2021 18:29 UTC | Elevation Oncology, Inc. ELEV · Entity 77243 | PurchaseCommon Stock | 187,500 | $16.00 | $3,000,000.00 |
DisclosureSEC source: 0001209191-21-044561 · doc4.xml · nonDerivative · entry 3 Aisling Capital IV, LP · CIK 0001652910 · 10% owner Aisling Capital Partners IV LLC · CIK 0001737019 · 10% owner Aisling Capital Partners IV, LP · CIK 0001737020 · 10% owner ELMS STEVE · CIK 0001250195 · Director · Managing Member SCHIFF ANDREW N · CIK 0001172252 · Managing Member Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,834,910 F2 · ownership.direct: The securities are directly held by Aisling Capital IV, LP ("Aisling"). Aisling Capital Partners IV, LP ("Aisling GP"), is the general partner of Aisling, and Aisling Capital Partners IV LLC ("Aisling Partners"), is the general partner of Aisling GP. The managers of Aisling Partners are Dr. Andrew Schiff and Steve Elms and may share voting power and dispositive powers over securities held by Aisling, and as a result, may be deemed to have beneficial ownership over such securities. Each of the reporting persons disclaims beneficial ownership of the reported securities except to the extent of such reporting person's pecuniary interest therein. Read SEC document |
| June 29, 2021 Filed Jul 1, 2021 18:29 UTC | Elevation Oncology, Inc. ELEV · Entity 77243 | ConversionCommon Stock | 458,360 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-21-044561 · doc4.xml · nonDerivative · entry 2 Aisling Capital IV, LP · CIK 0001652910 · 10% owner Aisling Capital Partners IV LLC · CIK 0001737019 · 10% owner Aisling Capital Partners IV, LP · CIK 0001737020 · 10% owner ELMS STEVE · CIK 0001250195 · Director · Managing Member SCHIFF ANDREW N · CIK 0001172252 · Managing Member Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,647,410 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: The Shares of the Issuer's Preferred Stock automatically converted on a 4.225582-for-one basis into the number of shares of the Issuer's Common Stock in shown in column 7 immediately upon the closing of the Issuer's initial public offering, and had no expiration date. F2 · ownership.direct: The securities are directly held by Aisling Capital IV, LP ("Aisling"). Aisling Capital Partners IV, LP ("Aisling GP"), is the general partner of Aisling, and Aisling Capital Partners IV LLC ("Aisling Partners"), is the general partner of Aisling GP. The managers of Aisling Partners are Dr. Andrew Schiff and Steve Elms and may share voting power and dispositive powers over securities held by Aisling, and as a result, may be deemed to have beneficial ownership over such securities. Each of the reporting persons disclaims beneficial ownership of the reported securities except to the extent of such reporting person's pecuniary interest therein. Read SEC document |
| June 29, 2021 Filed Jul 1, 2021 18:29 UTC | Elevation Oncology, Inc. ELEV · Entity 77243 | ConversionCommon Stock | 1,893,232 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-21-044561 · doc4.xml · nonDerivative · entry 1 Aisling Capital IV, LP · CIK 0001652910 · 10% owner Aisling Capital Partners IV LLC · CIK 0001737019 · 10% owner Aisling Capital Partners IV, LP · CIK 0001737020 · 10% owner ELMS STEVE · CIK 0001250195 · Director · Managing Member SCHIFF ANDREW N · CIK 0001172252 · Managing Member Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,189,050 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: The Shares of the Issuer's Preferred Stock automatically converted on a 4.225582-for-one basis into the number of shares of the Issuer's Common Stock in shown in column 7 immediately upon the closing of the Issuer's initial public offering, and had no expiration date. F2 · ownership.direct: The securities are directly held by Aisling Capital IV, LP ("Aisling"). Aisling Capital Partners IV, LP ("Aisling GP"), is the general partner of Aisling, and Aisling Capital Partners IV LLC ("Aisling Partners"), is the general partner of Aisling GP. The managers of Aisling Partners are Dr. Andrew Schiff and Steve Elms and may share voting power and dispositive powers over securities held by Aisling, and as a result, may be deemed to have beneficial ownership over such securities. Each of the reporting persons disclaims beneficial ownership of the reported securities except to the extent of such reporting person's pecuniary interest therein. Read SEC document |
| June 24, 2021 Filed Jun 28, 2021 18:18 UTC | Elevation Oncology, Inc. ELEV · Entity 77243 | GrantDirector Stock Option · Derivative | 31,238 | $0.00 Strike: $16.00 | $0.00 |
DisclosureSEC source: 0001209191-21-043527 · doc4.xml · derivative · entry 1 Aisling Capital IV, LP · CIK 0001652910 · 10% owner Aisling Capital Partners IV LLC · CIK 0001737019 · 10% owner Aisling Capital Partners IV, LP · CIK 0001737020 · 10% owner ELMS STEVE · CIK 0001250195 · Director · Managing Member SCHIFF ANDREW N · CIK 0001172252 · Managing Member Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 31,238 Underlying: Common Stock · 31,238 shares Expires 2031-06-23 F1 · derivative.exercise_date: This stock option was granted to Steven Elms, an employee of Aisling Capital, in his capacity as a director of the Issuer. Pursuant to the policies of Aisling Capital, Mr. Elms does not have any right to any of the Issuer's securities issued as part of his service on the Board and Aisling Capital is entitled to receive all of the pecuniary interest in the securities issued. The stock option vests as of 1/36 of the total shares monthly beginning on July 24, 2021 until fully vested, subject to the Reporting Person's provision of service to the Issuer on each vesting date. Read SEC document |
| December 02, 2019 Filed Dec 6, 2019 10:23 UTC | Zosano Pharma Corp ZSAN · Entity 12518 | GrantCommon Stock, par value of $0.0001 | 689,655 | $1.45 | $999,999.75 |
DisclosureSEC source: 0000899243-19-028646 · doc4.xml · nonDerivative · entry 1 Aisling Capital IV, LP · CIK 0001652910 · 10% owner Aisling Capital Partners IV, LP · CIK 0001737020 · 10% owner Aisling Capital Partners IV LLC · CIK 0001737019 · 10% owner ELMS STEVE · CIK 0001250195 · 10% owner SCHIFF ANDREW N · CIK 0001172252 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,718,226 F1 · ownership.direct: The securities are directly held by Aisling Capital IV, LP ("Aisling"), and may be deemed to be beneficially owned by Aisling Capital Partners IV, LP ("Aisling GP"), as general partner of Aisling, Aisling Capital Partners IV LLC ("Aisling Partners"), as general partner of Aisling GP, and each of the individual managing members and partners (collectively, the "Managers") of Aisling GP and Aisling Partners. The Managers of Aisling Partners are Dr. Andrew Schiff and Steve Elms. Read SEC document |
| July 15, 2019 Filed Jul 15, 2019 16:15 UTC | Viracta Therapeutics, Inc. SNSS · Entity 85616 | PurchaseCommon Stock | 2,500,000 | $0.60 | $1,500,000.00 |
DisclosureSEC source: 0000899243-19-019602 · doc4.xml · nonDerivative · entry 1 Aisling Capital IV, LP · CIK 0001652910 · 10% owner Aisling Capital Partners IV LLC · CIK 0001737019 · 10% owner Aisling Capital Partners IV, LP · CIK 0001737020 · 10% owner SCHIFF ANDREW N · CIK 0001172252 · 10% owner ELMS STEVE · CIK 0001250195 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 10,100,000 F1 · ownership.nature: Shares held by Aisling Capital IV, LP ("Aisling"). Aisling Capital Partners IV, LP ("Aisling GP"), is the general partner of Aisling. Aisling Capital Partners IV LLC ("Aisling Partners"), is the general partner of Aisling GP. The individual managing members ("the Aisling Managers"), of Aisling Partners are Andrew Schiff, M.D. and Steve Elms. By virtue of these relationships, Aisling GP, Aisling Partners and the Aisling Managers may be deemed to have voting and investment power over the shares held by Aisling. Each of the reporting persons, other than Aisling, disclaims beneficial ownership of the shares held by Aisling, except to the extent of any pecuniary interest therein, if any. Read SEC document |
| April 11, 2019 Filed Apr 12, 2019 16:15 UTC | Zosano Pharma Corp ZSAN · Entity 12518 | GrantCommon Stock, par value of $0.0001 | 428,571 | $3.50 | $1,499,998.50 |
DisclosureSEC source: 0000899243-19-010594 · doc4.xml · nonDerivative · entry 1 Aisling Capital IV, LP · CIK 0001652910 · 10% owner Aisling Capital Partners IV, LP · CIK 0001737020 · 10% owner Aisling Capital Partners IV LLC · CIK 0001737019 · 10% owner ELMS STEVE · CIK 0001250195 · 10% owner SCHIFF ANDREW N · CIK 0001172252 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,028,571 F1 · ownership.direct: The securities are directly held by Aisling Capital IV, LP ("Aisling"), and may be deemed to be beneficially owned by Aisling Capital Partners IV, LP ("Aisling GP"), as general partner of Aisling, Aisling Capital Partners IV LLC ("Aisling Partners"), as general partner of Aisling GP, and each of the individual managing members and partners (collectively, the "Managers") of Aisling GP and Aisling Partners. The Managers of Aisling Partners are Dr. Andrew Schiff and Steve Elms. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.